Skip to main content
. 2015 Nov 7;29(11):953–962. doi: 10.1007/s40263-015-0291-6

Fig. 2.

Fig. 2

Mean change from baseline in WFIRS-P scores at Visit 10 (last observation carried forward) by treatment response to GXR treatment; full analysis set (GXR all-active group). Responders are defined as subjects with ADHD-RS-IV Total score reduction from baseline ≥30 % and a CGI-I score of 1 or 2. WFIRS-P Weiss Functional Impairment Rating Scale–Parent Report, GXR guanfacine extended release, ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder, CGI-I Clinical Global Impressions–Improvement Scale. ***P <0.001